Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 19, 2018 | June 22, 2018 |
| Celldex Therapeutics, Inc.CLDX · Entity 4208 | Director | June 25, 2026 | June 29, 2026 |
| Matinas BioPharma Holdings, Inc.MTNB · Entity 8443 | Director | November 01, 2023 | November 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 19, 2018 · Filed June 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.75 · Expires 2028-06-19 | Direct | 22,000 |
Reported balance
After 2018-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-19 · Grant · Acquired 22,000 · Balance 22,000 |
Celldex Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.09 · Expires 2036-06-25 | Direct | 26,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 26,000 · Balance 26,000 F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.
Matinas BioPharma Holdings, Inc.
Report date November 01, 2023 · Filed November 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.21 · Expires 2033-11-01 | Direct | 437,244 |
Reported balance
After 2023-11-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-01 · Grant · Acquired 437,244 · Balance 437,244 F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2026 Filed Jun 29, 2026 20:07 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 26,000 | $0.00 Strike: $34.09 | $0.00 |
DisclosureSEC source: 0001218815-26-000002 · form4-06292026_080622.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,000 Underlying: Common Stock · 26,000 shares Expires 2036-06-25 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:08 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $19.53 | $0.00 |
DisclosureSEC source: 0001415889-25-016219 · form4-06092025_080631.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2035-06-05 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 20:03 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 16,500 | $0.00 Strike: $36.43 | $0.00 |
DisclosureSEC source: 0001415889-24-017140 · form4-06172024_080647.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 16,500 shares Expires 2034-06-13 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 20:49 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 437,244 | $0.00 Strike: $0.21 | $0.00 |
DisclosureSEC source: 0001493152-23-039336 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 437,244 Underlying: Common Stock · 437,244 shares Expires 2033-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 1, 2023. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| June 15, 2023 Filed Jun 20, 2023 20:08 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,300 | $0.00 Strike: $36.87 | $0.00 |
DisclosureSEC source: 0001415889-23-010034 · form4-06202023_080626.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,300 Underlying: Common Stock · 11,300 shares Expires 2033-06-15 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| November 14, 2022 Filed Nov 17, 2022 02:34 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 142,657 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001493152-22-032692 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,657 Underlying: Common Stock · 142,657 shares Expires 2032-11-14 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on November 14, 2022. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| June 22, 2022 Filed Jul 5, 2022 22:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 1,358,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 4 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 4,694,566 Read SEC document |
| June 22, 2022 Filed Jul 5, 2022 22:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 1,358,122 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 3 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT) Disclosed balance after: 0 Read SEC document |
| June 16, 2022 Filed Jun 17, 2022 20:08 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 13,600 | $0.00 Strike: $22.48 | $0.00 |
DisclosureSEC source: 0001415889-22-006705 · form4-06172022_010604.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,600 Underlying: Common Stock · 13,600 shares Expires 2032-06-16 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. F1 · date: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 20:17 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 90,882 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001493152-21-026989 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,882 Underlying: Common Stock · 90,882 shares Expires 2031-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2021. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| August 04, 2021 Filed Jul 5, 2022 22:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 494,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 3,336,444 Read SEC document |
| August 04, 2021 Filed Jul 5, 2022 22:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 494,622 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-22-018581 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 1,280,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-016565 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 2,841,822 Read SEC document |
| July 07, 2021 Filed Jul 9, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 1,280,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-016565 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT) Disclosed balance after: 1,358,122 Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 21:37 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionSeries B Preferred Stock · Derivative | 100 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000905718-21-000824 · matinasbio_fm4jun192021.xml · derivative · entry 5 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 21:37 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionCommon Stock, par value $0.0001 per share | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000824 · matinasbio_fm4jun192021.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 1,560,905 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: On June 19, 2021, pursuant to the Certificate of Designations of Preferences, Rights and Limitations of the Series B Preferred Stock (the "Certificate") of the Issuer, all shares of Series B Convertible Preferred Stock were mandatorily converted into shares of the Issuer's common stock. Each share of Series B Convertible Preferred Stock converted into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock were convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate. The Series B Convertible Preferred Stock had no expiration date. Read SEC document |
| June 19, 2021 Filed Jun 24, 2021 21:37 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-21-000824 · matinasbio_fm4jun192021.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 1,360,905 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 400 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:19 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $28.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006888 · edgar.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2031-06-17 F1 · security: Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 1,145,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 4 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 1,320,905 Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 1,145,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 3 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert Conrad 2019 Grantor Retained Annuity Trust (GRAT) Disclosed balance after: 0 Read SEC document |
| January 13, 2021 Filed May 24, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftSeries B Convertible Preferred Stock · Derivative | 100 | $1,000.00 Strike: $0.50 | $100,000.00 |
DisclosureSEC source: 0001493152-21-012764 · ownership.xml · derivative · entry 7 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 100 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| January 13, 2021 Filed May 24, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftSeries B Convertible Preferred Stock · Derivative | 100 | $1,000.00 Strike: $0.50 | $100,000.00 |
DisclosureSEC source: 0001493152-21-012764 · ownership.xml · derivative · entry 6 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F1 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| January 13, 2021 Filed May 24, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad, Susan Wachtel, Nancy Fallick, Trustees Disclosed balance after: 175,000 Read SEC document |
| January 13, 2021 Filed May 24, 2021 21:30 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-012764 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 494,622 Read SEC document |
| November 02, 2020 Filed Nov 10, 2020 21:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 122,605 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001493152-20-020921 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,605 Underlying: Common Stock · 122,605 shares Expires 2030-11-02 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2020. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| June 23, 2020 Filed Jun 25, 2020 01:00 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-011764 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,622 F1 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 300 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 12:03 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $10.38 | $0.00 |
DisclosureSEC source: 0001179110-20-007587 · edgar.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2030-06-18 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:10 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-010651 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert Conrad 2020 Grantor Retained Annuity Trust (GRAT) Disclosed balance after: 2,639,039 Read SEC document |
| June 04, 2020 Filed Jun 5, 2020 20:10 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-010651 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad and Judith Conrad, Trustees Disclosed balance after: 125,000 Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:01 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-009089 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad and Judith Conrad, Trustees Disclosed balance after: 2,764,039 Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:01 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock, par value $0.0001 per share | 2,639,039 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-009089 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert Conrad 2019 Grantor Retained Annuity Trust (GRAT) Disclosed balance after: 1,145,905 Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock, par value $0.0001 per share | 10,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-20-000123 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,622 F1 · shares: On December 31, 2019, the Reporting Person was issued 10,573 shares of common stock par value $.0001 per share pursuant to the Issuer's Amended and Restated 2013 Equity Incentive Plan. Such shares vest immediately upon grant. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 21:05 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 107,416 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0001493152-19-016456 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,416 Underlying: Common Stock · 107,416 shares Expires 2029-11-01 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2019. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| September 30, 2019 Filed Oct 2, 2019 22:13 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock, par value $0.0001 per share | 38,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 4 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,049 F3 · shares: On September 30, 2019, the Reporting Person was issued 38,066 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| July 29, 2019 Filed Oct 2, 2019 22:13 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionSeries A Preferred Stock · Derivative | 20,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014915 · ownership.xml · derivative · entry 8 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 200,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: Converts automatically into Common Stock upon the earlier of (i) notice by the Issuer to the holders that the Issuer elected to convert all outstanding shares of Class A Preferred, (ii) July 29, 2019, (iii) the approval of the Issuer's MAT2203 product candidate by the U.S. Food and Drug Administration or the European Medicines Agency (the "Regulatory Approval") or (iv) the Regulatory Approval of the Issuer's MAT2501 product candidate. Read SEC document |
| July 26, 2019 Filed Oct 2, 2019 22:13 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,983 F1 · kind: Stock dividend, payable to all holders of record of Series A Preferred Stock of 2.4 shares of Common Stock for each share of Series A Preferred Stock. Read SEC document |
| July 26, 2019 Filed Oct 2, 2019 22:13 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | ConversionCommon Stock, par value $0.0001 per share | 200,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,983 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 30, 2019 Filed Jul 2, 2019 22:38 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock, par value $0.0001 per share | 28,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-010196 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,983 F1 · shares: On June 30, 2019, the Reporting Person was issued 28,005 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 21, 2019 Filed Oct 2, 2019 22:13 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | OtherCommon Stock, par value $0.0001 per share | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-19-014915 · ownership.xml · nonDerivative · entry 3 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,983 F2 · kind: Stock dividend, payable to all holders of record of Series B Preferred Stock of 200 shares of Common Stock for each share of Series B Preferred Stock. Read SEC document |
| June 19, 2019 Filed Jun 20, 2019 20:26 UTC | Celldex Therapeutics, Inc. CLDX · Entity 4208 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 4,500 | $0.00 Strike: $2.78 | $0.00 |
DisclosureSEC source: 0001179110-19-007969 · edgar.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires 2029-06-19 F1 · security: Represents option granted by the Issuer pursuant to its 2008 Stock Option and Incentive Plan. Read SEC document |
| May 16, 2019 Filed May 20, 2019 22:38 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseCommon Stock, par value $0.0001 per share | 25,000 | $0.96 | $24,115.00 |
DisclosureSEC source: 0001493152-19-007947 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Herbert J. Conrad Trust u/a/d 3/4/2005, Herbert J Conrad and Judith Conrad, Trustees Disclosed balance after: 172,959 F1 · price: The price represents the weighted average purchase price for multiple transactions reported on this line. The prices of the transactions ranged from $0.9563 to $0.9650, inclusive. Upon request of the SEC staff, the reporting person will provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 31, 2019 Filed Apr 3, 2019 20:45 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 22,019 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000327 · conrad_fm4feb82019.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,019 F1 · shares: On March 31, 2019, the Reporting Person was issued 22,019 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 22:39 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GiftCommon Stock | 3,932,903 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000106 · conrad_fm4feb82019.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 21:02 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 40,337 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-19-000020 · ownership.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,032,903 F1 · shares: On December 31, 2018, the Reporting Person was issued 40,337 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 13:17 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000909 · ownership.xml · derivative · entry 2 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 Read SEC document |
| November 01, 2018 Filed Nov 5, 2018 13:17 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantStock option (right to buy) · Derivative | 128,299 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000905718-18-000909 · ownership.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,299 Underlying: Common Stock · 128,299 shares Expires 2028-10-31 F1 · derivative.exercise_date: The option award was made in accordance with the terms of the Issuer's Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). The option vests in equal monthly installments over a period of 12 months commencing on December 1, 2018. The exercise price is based on the closing price for the shares of the Common Stock on the date of grant in accordance with the terms of the 2013 Plan. Read SEC document |
| October 01, 2018 Filed Oct 3, 2018 20:25 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 26,087 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000817 · conrad-matinas_fm4jun212018.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,992,566 F1 · shares: On October 1, 2018, the Reporting Person was granted 26,087 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equit Compensation Plan. Such shares vest immediately upon grant. F1 · price: On October 1, 2018, the Reporting Person was granted 26,087 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equit Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 29, 2018 Filed Jul 11, 2018 20:44 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | GrantCommon Stock | 55,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000905718-18-000626 · conrad-matinas_fm4jun292018.xml · nonDerivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,966,479 F1 · shares: On June 29, 2018, the Reporting Person was granted 55,300 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. F1 · price: On June 29, 2018, the Reporting Person was granted 55,300 shares of common stock par value $.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant. Read SEC document |
| June 21, 2018 Filed Jun 22, 2018 20:20 UTC | Matinas BioPharma Holdings, Inc. MTNB · Entity 8443 | PurchaseSeries B Convertible Preferred Stock · Derivative | 100 | $1,000.00 Strike: $0.50 | $100,000.00 |
DisclosureSEC source: 0000905718-18-000582 · conrad-matinas_fm4jun212018.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Underlying: Common Stock · 200,000 shares Expires not disclosed F1 · derivative.exercise_date: On June 21, 2018, the Reporting Person purchased 100 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. F1 · derivative.expiration_date: On June 21, 2018, the Reporting Person purchased 100 shares of Series B Convertible Preferred Stock from the Issuer in a public offering. Each share of Series B Convertible Preferred Stock is convertible into 2,000 shares of the Issuer's common stock. The shares of Series B Convertible Preferred Stock are convertible at any time, at the holder's election, or upon certain mandatory conversion events set forth in the Certificate of Designations of Preferences, Rights and Limitations of Series B Preferred Stock of the Issuer. The Series B Convertible Preferred Stock has no expiration date. Read SEC document |
| June 19, 2018 Filed Jun 22, 2018 23:30 UTC | Arbutus Biopharma Corp ABUS · Entity 4953 | GrantDirector Stock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $6.75 | $0.00 |
DisclosureSEC source: 0001140361-18-029668 · doc1.xml · derivative · entry 1 CONRAD HERBERT J · CIK 0001218815 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Shares · 22,000 shares Expires 2028-06-19 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.